JP5643200B2 - 筋萎縮性側索硬化症および関連する運動ニューロン疾患の診断、処置および予防のための、ｆｕｓ／ｔｌｓベースの化合物および方法 - Google Patents

筋萎縮性側索硬化症および関連する運動ニューロン疾患の診断、処置および予防のための、ｆｕｓ／ｔｌｓベースの化合物および方法 Download PDF

Info

Publication number
JP5643200B2
JP5643200B2 JP2011520029A JP2011520029A JP5643200B2 JP 5643200 B2 JP5643200 B2 JP 5643200B2 JP 2011520029 A JP2011520029 A JP 2011520029A JP 2011520029 A JP2011520029 A JP 2011520029A JP 5643200 B2 JP5643200 B2 JP 5643200B2
Authority
JP
Japan
Prior art keywords
fus
tls
als
gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011520029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528903A (ja
JP2011528903A5 (enExample
Inventor
クフャトコフスキ，トーマス，ジェイ．
ブラウン，ロバート，エイチ．
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション, ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2011528903A publication Critical patent/JP2011528903A/ja
Publication of JP2011528903A5 publication Critical patent/JP2011528903A5/ja
Application granted granted Critical
Publication of JP5643200B2 publication Critical patent/JP5643200B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
JP2011520029A 2008-07-22 2009-07-21 筋萎縮性側索硬化症および関連する運動ニューロン疾患の診断、処置および予防のための、ｆｕｓ／ｔｌｓベースの化合物および方法 Active JP5643200B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13568908P 2008-07-22 2008-07-22
US61/135,689 2008-07-22
PCT/US2009/004205 WO2010011283A2 (en) 2008-07-22 2009-07-21 Fus/tls-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases

Publications (3)

Publication Number Publication Date
JP2011528903A JP2011528903A (ja) 2011-12-01
JP2011528903A5 JP2011528903A5 (enExample) 2012-09-06
JP5643200B2 true JP5643200B2 (ja) 2014-12-17

Family

ID=41570769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011520029A Active JP5643200B2 (ja) 2008-07-22 2009-07-21 筋萎縮性側索硬化症および関連する運動ニューロン疾患の診断、処置および予防のための、ｆｕｓ／ｔｌｓベースの化合物および方法

Country Status (4)

Country Link
US (3) US9150860B2 (enExample)
JP (1) JP5643200B2 (enExample)
CA (1) CA2731643C (enExample)
WO (1) WO2010011283A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150860B2 (en) 2008-07-22 2015-10-06 The General Hospital Corporation FUS/TLS-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases
US12060396B2 (en) 2013-04-11 2024-08-13 Vanderbilt University Fused in sarcoma (FUS) nuclear translocation inhibitors for preventing fibrosis
JP6342627B2 (ja) * 2013-08-02 2018-06-13 国立大学法人 東京大学 筋萎縮性側索硬化症の新規病因遺伝子
CN110770336B (zh) * 2017-03-22 2023-09-12 神济昌华(北京)生物科技有限公司 用于als的突变型fus模型
WO2018170796A1 (en) * 2017-03-22 2018-09-27 Tsinghua University Trim72 as potential therapeutic target for als through ubiquitinating mutant fus protein
WO2020096103A1 (ko) * 2018-11-09 2020-05-14 순천향대학교 산학협력단 신경계 퇴행성 질환 진단용 마커 및 치료용 조성물
EP3892283A1 (en) * 2020-04-09 2021-10-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acids encoding human fus protein and use in the treatment of amyotrophic lateral sclerosis (als)
US20240229025A1 (en) * 2020-09-09 2024-07-11 Ohara Pharmaceutical Co., Ltd. siRNA AND USE THEREOF
WO2022082199A1 (en) * 2020-10-16 2022-04-21 Pluripotent Diagnostics Corp. Method for detecting amyotrophic lateral sclerosis
WO2023060132A1 (en) * 2021-10-05 2023-04-13 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Allele specific editing to treat fus-induced neurodegeneration
WO2023171587A1 (ja) * 2022-03-08 2023-09-14 大原薬品工業株式会社 変異ＦＵＳの発現を選択的に抑制する修飾ｓｉＲＮＡ
CN116042619B (zh) * 2022-12-19 2023-09-08 神济昌华(北京)生物科技有限公司 用于构建人源FUS基因敲入的ALS果蝇模型的gRNA组合及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5843641A (en) 1993-02-26 1998-12-01 Massachusetts Institute Of Technology Methods for the daignosis, of familial amyotrophic lateral sclerosis
JP2002306179A (ja) * 2001-04-16 2002-10-22 Japan Science & Technology Corp Ａｌｓ２ｃｒ６遺伝子と、２型筋萎縮性側索硬化症の診断方法
CA2521999A1 (en) * 2002-12-20 2004-09-02 Biotrove, Inc. Assay apparatus and method using microfluidic arrays
AU2004245998A1 (en) 2003-06-04 2004-12-16 The Government of the United States as represented by The Secretary of the Department of Health and Human Services, Centres for Disease Control and Prevention PNI microarray and uses
US20070009899A1 (en) * 2003-10-02 2007-01-11 Mounts William M Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases
EP1805197A1 (en) * 2004-09-27 2007-07-11 Med Biogene Inc Hematological cancer profiling system
US20070202537A1 (en) 2005-12-05 2007-08-30 Prosetta Corporation Biomarkers for als
WO2008085984A1 (en) 2007-01-08 2008-07-17 Androscience Corporation Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and uses thereof
US9150860B2 (en) 2008-07-22 2015-10-06 The General Hospital Corporation FUS/TLS-based compounds and methods for diagnosis, treatment and prevention of amyotrophic lateral sclerosis and related motor neuron diseases

Also Published As

Publication number Publication date
JP2011528903A (ja) 2011-12-01
CA2731643A1 (en) 2010-01-28
WO2010011283A2 (en) 2010-01-28
WO2010011283A3 (en) 2010-05-14
CA2731643C (en) 2020-05-05
US20160177389A1 (en) 2016-06-23
US20120046341A1 (en) 2012-02-23
US20210388444A1 (en) 2021-12-16
US9150860B2 (en) 2015-10-06
US11041204B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
JP5643200B2 (ja) 筋萎縮性側索硬化症および関連する運動ニューロン疾患の診断、処置および予防のための、ｆｕｓ／ｔｌｓベースの化合物および方法
US20080299125A1 (en) Genetic basis of treatment response in depression patients
US10266896B2 (en) Genetic alterations on chromosome 16 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
CN101501194A (zh) 老年性黄斑变性的预防和治疗
Wang et al. Whole exome sequencing in unexplained recurrent miscarriage families identified novel pathogenic genetic causes of euploid miscarriage
WO2009144480A1 (en) Treatment and diagnosis of behavioural disorders
US9926600B2 (en) Genetic alterations associated with type I diabetes and methods for use thereof for diagnosis and treatment
JP6095889B2 (ja) 染色体２１ｑ、６ｑ、および１５ｑの遺伝子変異およびこれらを使用して１型糖尿病を診断および治療する方法
US7060457B2 (en) Aberrant glutamate transporters and methods of use
US7432052B2 (en) Method and identification of downstream mRNA ligands to FMRP and their role in fragile X syndrome and associated disorders
US20220349008A1 (en) Novel genetic markers for postural orthostatic tachycardia syndrome (pots) and methods of use thereof for diagnosis and treatment of the same
JP2008504838A (ja) Ｐｒｋｃｂ１をコードするヒト自閉症感受性遺伝子およびその使用
Li et al. Polymorphisms of presenilin-1 gene associate with dilated cardiomyopathy susceptibility
JP5422805B2 (ja) 新規糖尿病性腎症感受性遺伝子
US20220316008A1 (en) Compositions comprising rare genetic sequence variants associated with pulmonary function and methods of use thereof for diagnosis and treatment of asthma in african american patients
JP4845486B2 (ja) 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法
KR101130886B1 (ko) 파킨슨병의 진단에 적용될 수 있는 병리유전학적 마커 확보를 위한 디제이-1 상실 세포주
JP5235448B2 (ja) 糖尿病性腎症感受性遺伝子、および糖尿病性腎症の予防または治療剤の有効成分のスクリーニング方法
US10125395B2 (en) Genetic alterations and methods of use thereof for the diagnosis and treatment of type I diabetes
WO2013142286A1 (en) Genetic alterations associated with autism and the autistic phenotype in the israeli population and methods of use thereof for the diagnosis and treatment of autism
KR20100107385A (ko) 파킨슨병의 진단에 적용될 수 있는 병리유전학적 마커 확보를 위한 디제이-1 상실 세포주

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140611

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140711

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140930

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141030

R150 Certificate of patent or registration of utility model

Ref document number: 5643200

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250